Denosumab for prevention of fractures in postmenopausal women with osteoporosis - Wikidata - awgldk - TriplyDB

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

http://www.wikidata.org/entity/Q28254528

about

Reproducibility of results in preclinical studies: a perspective from the bone field The pharmacological management of osteoporosis Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer European guidance for the diagnosis and management of osteoporosis in postmenopausal women Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease Treating osteoporosis The Relationship between Metabolic Syndrome and Osteoporosis: A Review Management of chronic pain in osteoporosis: challenges and solutions Hypercalcemia of Malignancy: An Update on Pathogenesis and Management Prevention and treatment of bone fragility in cancer patient Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence Recent developments in osteogenesis imperfecta Emerging Therapies for Osteoporosis Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Calcium intake and bone mineral density: systematic review and meta-analysis Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients Osteochemonecrosis: an overview Nuclear receptors in bone physiology and diseases Osteoporosis Treatment: When to Discontinue and When to Re-start Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective Treatment of primary osteoporosis in men Screening, diagnosis and treatment of osteoporosis: a brief review A review of denosumab for the treatment of osteoporosis Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives Denosumab for the treatment of osteoporosis A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures An overview on the treatment of postmenopausal osteoporosis New antiresorptive therapies for postmenopausal osteoporosis Denosumab: mechanism of action and clinical outcomes Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor Bone anabolics in osteoporosis: Actuality and perspectives Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures.The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review)

P2860

Q24289530-46B3AFD3-01FA-48C6-A2BB-3FD442212B53 Q24605290-1088701E-F968-46E1-B634-6D40C83AFA38 Q24605866-4D76BC7F-235C-4918-9E01-5AF185C90F60 Q24612411-C819BEC8-B546-4578-8626-AA662756E1A1 Q24623768-3460298E-85DD-499B-9E66-02CD4AD47D52 Q24658507-69DCCEAF-8A91-42DB-8424-1C0C7FD9CF29 Q26744057-E73A689F-7A49-4332-A764-A714E6DE0F1B Q26747224-4250E240-FA2D-402E-83A9-05423D6916DD Q26747363-81CC5284-C694-4A73-8B9E-17F6EE7A9447 Q26747451-A1CBDAA3-B6D6-40D3-AF5B-417EFB88DD15 Q26751333-0DA4AFE1-43C0-4C32-970D-C0EB17277320 Q26771719-187B6AEF-4F31-4D64-927C-0092ABF32134 Q26775765-37105BA2-C765-4934-872D-21788AE70B70 Q26778216-190A4E82-98D0-432E-A626-AF5137D11683 Q26778291-8088794D-045B-4E7A-9E29-52CB96CF5041 Q26781674-8B172263-338B-4C79-B78F-7BC84AF96E3D Q26782109-C4EEE9F0-3DC3-4019-BD1B-85E30EBECA59 Q26782621-0C56E4F5-A481-4190-A595-74B5D89FF31F Q26784337-DA40DF33-45A9-4F57-B03B-E1AF9062CBF3 Q26824762-AF57A0C9-D49A-4929-A2B3-010AE95D0772 Q26827072-6635F37F-4558-459C-973D-41E96B833338 Q26853017-5CF71C3A-4410-4BC2-A21E-85DF756B3C10 Q26858980-AF197E72-DE10-4C35-966F-523B64D99CCE Q26864207-FE4648BA-3790-4C02-BEDE-C7B5B7B5A10E Q26991748-6B63D65E-2260-44CD-92F7-CDBC5630F026 Q26996726-37533307-8A3D-4A61-838C-EC725F60A0F6 Q27005894-E37C0BF7-27F2-41AF-8FA7-EF4477E55CDD Q27005978-AA7B1CBD-FAA3-45D2-9647-4E79893315CF Q27009275-D0F25187-CAA0-43FE-83F5-DA0B89AC39E3 Q27009420-B3D1DDAC-4B26-46F6-ADDC-CFD2632B3881 Q27013070-31E0AD1D-1303-4C81-8C00-4CFB4C038E5F Q27014775-57D26448-8079-418D-93C9-C257A3D94DA7 Q27015899-259FC673-2F43-4EB9-9F68-89B90F3AE520 Q27021268-79ACDF64-E8B4-46E3-9A15-3B2F5E1DF447 Q27665673-538D5F6F-0570-439F-9CF1-6424DE2524E4 Q27676827-7390C0DE-A514-4BBD-BDA0-896112405056 Q27691122-423F3C34-7FD8-428C-963A-297DC89C3C14 Q27693845-64E3EC1E-89B1-4CC6-9C1B-31773276A628 Q28080673-3503891A-28A1-47C9-835D-3C0657C3AC57 Q28083206-06546F4F-04AA-4AA8-A489-0112D980150E

P2860

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

http://www.wikidata.org/entity/Q28254528

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@ast

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@en

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@nl

type

label

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@ast

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@en

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@nl

prefLabel

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@ast

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@en

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@nl

P1433

Q28254528-54B194B4-E619-44DB-BBCB-94C8388E55A9

P1476

Q28254528-AB0DC3C0-AC17-4FBA-B912-50388A169E0C

P2093

Q28254528-120C933A-A622-4BE2-AC81-8BD103588927

Q28254528-15B90470-4F1C-447B-83A3-3D56B0047A86

Q28254528-24EF70CA-8D44-4C94-BA98-99D47E5EE697

Q28254528-4D1FED5A-79A9-4253-81A5-48FD4D1BD2FA

Q28254528-502599AE-E0A7-4F7E-983C-70DEB9EC8923

Q28254528-792C18D6-C02B-4C34-94D9-BDAA6031D340

Q28254528-971A291B-333A-464B-8197-CAC103E1EDFD

Q28254528-9E9BEA62-D9C1-4AAF-946F-138437BB367B

Q28254528-BAFE8188-EE2B-467F-A05D-663B693441F2

Q28254528-BF499D78-BF8B-4AED-9320-C0AC2F110E8D

P304

Q28254528-3FC1FA99-FFB5-4D68-A595-039A138F4751

P31

Q28254528-9D0D712C-72C4-4844-8B97-6CBB62C27A61

P3181

Q28254528-EE0D0881-2EEA-487B-9747-405EC1DF6730

P356

Q28254528-ABDA72B2-ADB4-40BB-A96C-1CBF19591B10

P407

Q28254528-F55C93B7-3305-4F78-AA18-DD797B7A50C3

P433

Q28254528-675AB9AE-A19F-45EE-897F-0127F0F65A74

P478

Q28254528-28A02E9C-2154-4C49-9C58-72D2C1919302

P50

Q28254528-0C9DCDDD-8998-4A4C-8073-33E53198DA08

Q28254528-F01F8A27-B6B8-415B-AF27-40F64031CC76

P577

Q28254528-30836ACD-3668-479F-BA50-4D3AC65CA8A6

P698

Q28254528-7E404F59-4D39-44E2-BD77-47436F415C90

P921

Q28254528-51F80798-4C83-4618-B9F2-6ADDA1C516FD

P3181

P356

P1433

The New England Journal of Medicine

P1476

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

@en

P2093

Andrea Wang

http://www.w3.org/2001/XMLSchema#string

Cesar Libanati

http://www.w3.org/2001/XMLSchema#string

Claus Christiansen

http://www.w3.org/2001/XMLSchema#string

Ethel S Siris

http://www.w3.org/2001/XMLSchema#string

Holly B Zoog

http://www.w3.org/2001/XMLSchema#string

Javier San Martin

http://www.w3.org/2001/XMLSchema#string

Jose Zanchetta

http://www.w3.org/2001/XMLSchema#string

Matt Austin

http://www.w3.org/2001/XMLSchema#string

Pierre Delmas

http://www.w3.org/2001/XMLSchema#string

Richard Eastell

http://www.w3.org/2001/XMLSchema#string

P304

756-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

329656

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0809493

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P50

Michael R McClung

P577

2009-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19671655

http://www.w3.org/2001/XMLSchema#string

P921